Our Financial Restructuring:
Strengthening Endo for Tomorrow

A Message from Endo

To Our Valued Stakeholders:

Endo is moving forward with an important development in our ongoing business transformation that will put us in a stronger financial position for the future. On August 16, 2022, we initiated an in-court financial restructuring process after reaching an agreement with our senior debtholders on a transaction that would substantially reduce our debt and address opioid-related and other claims without the need for continued costly, time-consuming litigation.  

We are entering this process with ample liquidity to support our day-to-day operations, a portfolio of high-value products, and a demonstrated ability to bring innovative medications and new treatments to market. We will continue to invest in and execute across our core areas of growth.

Our momentum and commitment to our mission, customers, patients, team members, and communities will not change. We look forward to emerging from this process better positioned to continue helping everyone we serve live their best lives.

Above all, we are grateful for your ongoing support as we work to strengthen Endo for tomorrow.

Blaise Coleman, CEO of Endo headshot

Blaise Coleman
President & CEO

Blaise Coleman, CEO of Endo headshot

Blaise Coleman
President & CEO

A Message from Endo

To Our Valued Stakeholders:

Endo is moving forward with an important development in our ongoing business transformation that will put us in a stronger financial position for the future. On August 16, 2022, we initiated an in-court financial restructuring process after reaching an agreement with our senior debtholders on a transaction that would substantially reduce our debt and address opioid-related and other claims without the need for continued costly, time-consuming litigation.  

We are entering this process with ample liquidity to support our day-to-day operations, a portfolio of high-value products, and a demonstrated ability to bring innovative medications and new treatments to market. We will continue to invest in and execute across our core areas of growth.

Our momentum and commitment to our mission, customers, patients, team members, and communities will not change. We look forward to emerging from this process better positioned to continue helping everyone we serve live their best lives.

Above all, we are grateful for your ongoing support as we work to strengthen Endo for tomorrow.

Blaise Coleman, CEO of Endo headshot

Blaise Coleman
President & CEO

A Message from Endo

To Our Valued Stakeholders:

Endo is moving forward with an important development in our ongoing business transformation that will put us in a stronger financial position for the future. On August 16, 2022, we initiated an in-court financial restructuring process after reaching an agreement with our senior debtholders on a transaction that would substantially reduce our debt and address opioid-related and other claims without the need for continued costly, time-consuming litigation.  

We are entering this process with ample liquidity to support our day-to-day operations, a portfolio of high-value products, and a demonstrated ability to bring innovative medications and new treatments to market. We will continue to invest in and execute across our core areas of growth.

Our momentum and commitment to our mission, customers, patients, team members, and communities will not change. We look forward to emerging from this process better positioned to continue helping everyone we serve live their best lives.

Above all, we are grateful for your ongoing support as we work to strengthen Endo for tomorrow.

About Our Financial Restructuring

This is a significant milestone for Endo.

We will be able to further advance our strategic priorities to create compelling value for our stakeholders over the long term.

We will be able to further advance our strategic priorities to create compelling value for our stakeholders over the long term.

Press Releases